Dapsone and body mass index in subjects with multibacillary leprosy.

Abstract

BACKGROUND:

The physiological changes in obese subjects can modify the pharmacokinetic profiles of drugs influencing the therapeutic efficacy.

METHODS:

In this study, the authors compare plasma dapsone trough levels of multibacillary leprosy subjects stratified by body mass index (BMI) to evaluate if obesity plays a significant role on drug levels. The relationship between drug levels and BMI was also determined. Dapsone was measured by high-performance liquid chromatography and BMI based on World Health Organization criteria.

RESULTS:

At steady state, the median plasma dapsone trough level was significantly lower in obesity class 2 group, when compared with other groups, but they were similar between normal weight and preobesity groups. A weak association between drug levels and BMI was observed.

CONCLUSIONS:

Obesity promotes a significant reduction in plasma dapsone trough levels of subjects with multibacillary leprosy with a weak association between drug levels and BMI.

• Authors: Fernanda M L Moura, Rosa M Dias, Eliete C Araujo, Laélia M B F Brasil, Michelle V D Ferreira, Jose L F Vieira
• Journal: Therapeutic drug monitoring (Ther Drug Monit) Vol. 36 Issue 2 Pg. 261-3 (Apr 2014) ISSN: 1536-3694 [Electronic] United States
• PMID: 24232126 (Publication Type: Journal Article, Observational Study)

Chemical References

• Leprostatic Agents
• Dapsone

Topics

• Adult
• Body Mass Index
• Chromatography, High Pressure Liquid
• Dapsone (blood, pharmacokinetics)
• Humans
• Leprostatic Agents (blood, pharmacokinetics)
• Leprosy, Multibacillary (blood, complications, drug therapy)
• Male
• Middle Aged
• Obesity (blood, complications)